I'm LongbridgeAI, I can summarize articles.RPM International (RPM.US) kicked off the earnings season with organic sales growth of 5% in Q1 2026, fueled by infrastructure bill-driven demand for industrial coatings. The momentum rippled across niche manufacturers: Ormat Technologies (ORMP.US) secured Nevada geothermal expansion approvals last month, while Comtech Telecommunications (CTMX.US) landed a $120M satellite comms contract with defense agencies. Biotech saw sharp divergence—Kinnate Biopharma (KNRX.US) extended its Merck partnership after positive oncology trial data, but Voyager Therapeutics (VOGX.US) reversed course following FDA clinical hold. MoneyLion (MNY.US) pivoted to embedded insurance saw 30% user retention jump, and Traverse Biotech (TRAW.US) advanced rare-disease therapy into fast-track review. Lattice Semiconductor (LSTA.US) reported AI chip demand outpacing supply despite tariff headwinds. Two ETFs—MMSD.US and OOSB.US—sucked in $450M combined inflows as small-cap value bets gained traction.
